Contineum Therapeutics (NASDAQ:CTNM) Rating Increased to Hold at Wall Street Zen

Contineum Therapeutics (NASDAQ:CTNM) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other equities analysts also recently issued reports on CTNM. Robert W. Baird lowered their price objective on Contineum Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Monday, November 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Wednesday, January 21st. Leerink Partners started coverage on Contineum Therapeutics in a research report on Thursday, November 13th. They issued an “outperform” rating and a $22.00 price objective for the company. Morgan Stanley restated an “equal weight” rating and set a $14.00 target price (down previously from $23.00) on shares of Contineum Therapeutics in a research report on Thursday, January 8th. Finally, Royal Bank Of Canada decreased their target price on Contineum Therapeutics from $25.00 to $22.00 and set an “outperform” rating for the company in a research note on Friday, November 21st. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

Contineum Therapeutics Stock Down 3.0%

Shares of Contineum Therapeutics stock opened at $14.44 on Friday. The stock has a market cap of $421.36 million, a price-to-earnings ratio of -6.42 and a beta of 1.18. Contineum Therapeutics has a twelve month low of $3.35 and a twelve month high of $16.01. The company’s fifty day moving average is $12.48 and its 200 day moving average is $11.13.

Hedge Funds Weigh In On Contineum Therapeutics

Large investors have recently modified their holdings of the company. Geode Capital Management LLC increased its stake in Contineum Therapeutics by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 213,869 shares of the company’s stock valued at $2,446,000 after purchasing an additional 2,819 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Contineum Therapeutics during the fourth quarter worth about $43,000. Strs Ohio acquired a new stake in shares of Contineum Therapeutics in the 1st quarter worth about $27,000. Bank of America Corp DE lifted its position in Contineum Therapeutics by 500.0% in the 3rd quarter. Bank of America Corp DE now owns 7,236 shares of the company’s stock valued at $85,000 after acquiring an additional 6,030 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new position in Contineum Therapeutics during the 2nd quarter valued at about $43,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.